ParaguayTuberculosis profile
Population  2017 6.8 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.27 (0.21–0.34) 3.9 (3.1–4.9)
Mortality (HIV+TB only) 0.041 (0.03–0.055) 0.61 (0.44–0.8)
Incidence  (includes HIV+TB) 3 (2.5–3.4) 44 (37–50)
Incidence (HIV+TB only) 0.26 (0.22–0.3) 3.8 (3.2–4.4)
Incidence (MDR/RR-TB)** 0.067 (0.022–0.14) 0.99 (0.32–2)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.2 (0.15–0.24) 0.72 (0.57–0.88) 0.92 (0.74–1.1)
Males 0.17 (0.13–0.2) 1.9 (1.5–2.3) 2 (1.6–2.5)
Total 0.36 (0.3–0.42) 2.6 (2.2–3) 3 (2.5–3.4)
TB case notifications, 2017  
Total cases notified 2 770
Total new and relapse 2 579
          - % tested with rapid diagnostics at time of diagnosis 32%
          - % with known HIV status 85%
          - % pulmonary 91%
          - % bacteriologically confirmed among pulmonary 78%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.11 (0.08–0.13)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 185 8%
          - on antiretroviral therapy 162 88%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  79
(26–130)
Estimated % of TB cases with MDR/RR-TB 0.9% (0.08–2.7) 15% (5.6–27)  
% notified tested for rifampicin resistance 44% 69% 1 341
MDR/RR-TB cases tested for resistance to second-line drugs   4
Laboratory-confirmed cases MDR/RR-TB: 9, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 9, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 67% 2 505
Previously treated cases, excluding relapse, registered in 2016 50% 173
HIV-positive TB cases registered in 2016 28% 216
MDR/RR-TB cases started on second-line treatment in 2015 46% 13
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 10%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
52% (48–57)
TB financing, 2018  
National TB budget (US$ millions) 25
Funding source: 13% domestic, 6% international, 81% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-05-26 Data: www.who.int/tb/data